Gould, Samuel I. http://orcid.org/0000-0003-2617-5215
Wuest, Alexandra N.
Dong, Kexin http://orcid.org/0000-0003-1379-3890
Johnson, Grace A.
Hsu, Alvin http://orcid.org/0000-0003-4034-2788
Narendra, Varun K.
Atwa, Ondine
Levine, Stuart S. http://orcid.org/0000-0001-7363-562X
Liu, David R. http://orcid.org/0000-0002-9943-7557
Sánchez Rivera, Francisco J. http://orcid.org/0000-0002-8466-8563
Article History
Received: 11 September 2023
Accepted: 9 February 2024
First Online: 12 March 2024
Competing interests
: The authors declare competing financial interests: D.R.L. is a consultant and/or equity owner for Prime Medicine, Beam Therapeutics, Pairwise Plants, Chroma Medicine and Nvelop Therapeutics, companies that use or deliver genome editing or epigenome engineering agents. The remaining authors declare no competing interests.